SWOG clinical trial number
CTSU/C10501
A Phase III intergroup CLL study of asymptomatic patients with untreated chronic lymphocytic leukemia randomized to early intervention versus observation with later treatment in the high risk genetic subset with IgVH unmutated disease
Closed
Phase
Abbreviated Title
CALGB - Phase III Early Intervention vs. Observation w/ Later Treatment for IgVH unmutated CLL
Activated
09/15/2008
Closed
01/05/2010
Participants
CTSU
Research committees
Leukemia
Treatment
Allopurinol
Fludarabine Phosphate
Rituximab
Eligibility Criteria Expand/Collapse
The Southwest Oncology Group has endorsed this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.
Please contact the CTSU directly by phone (888/823-5923) or on the CTSU website (http://www.ctsu.org/) for more information and registration procedures.
Please contact the CTSU directly by phone (888/823-5923) or on the CTSU website (http://www.ctsu.org/) for more information and registration procedures.
Other Clinical Trials
SWOG Clinical Trial Number
S2507
A Phase II Randomized Study of Blinatumomab with or without Revumenib for Patients with KMT2A Translocation B-Cell Acute Lymphoblastic Leukemia (ALL)/ Acute Leukemia With Ambiguous Lineage (ALAL) with Persistent Measurable Residual Disease (MRD)
Research Committee(s)
Leukemia
Other
Activated
09/22/2026
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
S2504
A Randomized Phase III Study of PIRtobrutinib plus R-CHOP vs. R-CHOP for Patients with Previously UntreateD RIchter TrAnsforMation (RT) (pirAMID)
Research Committee(s)
Leukemia
Lymphoma
Activated
06/01/2026
Accrual
2%
Open
Phase
SWOG Clinical Trial Number
CTSU/A042302
Phase III Evaluation of Fixed Duration Zanubrutinib Plus Sonrotoclax-Based Therapy Compared to Continuous Zanubrutinib in Previously Untreated Older Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Research Committee(s)
Leukemia
Activated
03/06/2026
Open
Phase